Investor Relations

Investor Overview Image

Prothena Corporation plc (Nasdaq: PRTA) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel antibodies that are directed towards diseases that involve protein misfolding or cell adhesion. These potential therapies have a number of indications including AL and AA forms of amyloidosis (NEOD001), Parkinson’s disease and related synucleinopathies (PRX002), and novel cell adhesion targets involved in autoimmune diseases and cancers (PRX003).

$ 23.51
0.61 (2.66%)

Day High: 23.68
Day Low:  22.30
Volume:    295,700
4:00 PM ET
Sep 19, 2014

Delayed ~20 min., by eSignal.

Press Releases

Aug 26, 2014
Aug 18, 2014